Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 165 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Actinic Keratoses Clear all
Terminated Not applicable Interventional Results available

Photodynamic Therapy Using Topical Aminolevulinic Acid in Treating Patients With Actinic Keratosis

NCT00524485
View directory record Official record
Conditions
Precancerous/Nonmalignant Condition
Interventions
aminolevulinic acid, laser therapy
Drug · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Not applicable Interventional

Pilot Study of the Pragmatic Use of Mobile Phone Based Follow up of Actinic Keratoses Treated With Topical 5-fluorouracil

NCT02938715
View directory record Official record
Conditions
Actinic Keratosis
Interventions
teledermatology feedback
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2018 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Development and Validation of a Quality of Life Instrument for Actinic Keratosis

NCT01444989
View directory record Official record
Conditions
Actinic Keratosis
Interventions
AKRQ questionnaire, Skindex-16, DLQI, Skin Health Calculator
Other
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Jul 21, 2026, 11:25 AM EDT
Not listed Phase 3 Interventional

T4N5 Liposome Lotion Compared With Placebo Lotion for Preventing Actinic Keratoses in Patients With Xeroderma Pigmentosum

NCT00002811
View directory record Official record
Conditions
Precancerous Condition
Interventions
liposomal T4N5 lotion
Drug
Lead sponsor
Applied Genetics
Industry
Eligibility
2 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
7
States / cities
Miami Beach, Florida • Ann Arbor, Michigan • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Phase 2 Interventional Results available

ACT01 in Combination With Comp01-04 in Patients With Actinic Keratosis

NCT02126670
View directory record Official record
Conditions
Actinic Keratosis
Interventions
ACT01, Comp01, Comp02, Comp03, Comp04
Drug
Lead sponsor
Promius Pharma, LLC
Industry
Eligibility
30 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
4
States / cities
San Diego, California • Louisville, Kentucky • High Point, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2016 · Synced Jul 21, 2026, 11:25 AM EDT
Enrolling by invitation Phase 4 Interventional

Efficacy and Safety of Cryotherapy Versus 5-Fluorouracil in the Treatment of Actinic Keratosis

NCT06461442
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Cryotherapy, 5Fluorouracil
Procedure · Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

An Open-Label 18-Month Safety Study of Fluorouracil Cream 0.5% for the Treatment of Actinic Keratoses

NCT00377273
View directory record Official record
Conditions
Actinic Keratoses
Interventions
fluorouracil cream 0.5%
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 9, 2008 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Phase 3 Interventional

Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp

NCT05662202
View directory record Official record
Conditions
Actinic Keratoses
Interventions
BF-200 ALA and red light LED lamp, Vehicle and red light LED lamp
Combination Product
Lead sponsor
Biofrontera Inc.
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
14
States / cities
Phoenix, Arizona • Greenwood Village, Colorado • Delray Beach, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 21, 2026, 11:25 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study

NCT04269395
View directory record Official record
Conditions
Keratosis, Actinic
Interventions
MAL Cream, Vehicle cream
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
52
States / cities
Fort Smith, Arkansas • Encinitas, California • Fountain Valley, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Jul 21, 2026, 11:25 AM EDT
Completed No phase listed Observational

A Long Term Follow up Study of Patients Who Have Completed the PEP005-020 Study

NCT00952783
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Lesion count
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
Orange Park, Florida • Newnan, Georgia • Snellville, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Photoirritation Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers

NCT00850811
View directory record Official record
Conditions
Actinic Keratosis
Interventions
PEP005 (ingenol mebutate) Gel
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 8, 2015 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Phase 4 Interventional Results available

Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses

NCT00774787
View directory record Official record
Conditions
Actinic Keratoses
Interventions
imiquimod 5% cream
Drug
Lead sponsor
Rigel Dermatology
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
3
States / cities
St. Petersburg, Florida • Henderson, Nevada • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 6, 2016 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Phase 3 Interventional Results available

A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)

NCT00916006
View directory record Official record
Conditions
Actinic Keratosis
Interventions
PEP005 Gel, Vehicle gel
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
19
States / cities
Los Angeles, California • Oceanside, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Not applicable Interventional Results available

Validation of SHADE a Mobile Technology for Monitoring of Ultraviolet Exposure

NCT03315286
View directory record Official record
Conditions
Skin Cancer, Actinic Keratoses, Ultraviolet-Induced Change in Normal Skin, Behavior, Health, Behavior, Risk Reduction
Interventions
SHADE Ultraviolet Sensor, Standard of care counseling
Device · Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 80 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Phase 2 Interventional Results available

Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream

NCT03914417
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Imiquimod 3.75% Cream
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Phase 2 Interventional

Imaging Techniques to Monitor Photosensitizer and sO2 Levels During Photodynamic Therapy of Actinic Keratoses

NCT05923060
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Topical Aminolevulinate, Photodynamic therapy (PDT), Red light illumination
Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Phase 1 Interventional Results available

Bioequivalence Study of Two Imiquimod Cream 5%

NCT00828568
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Imiquimod 5% manufactured by Taro, Aldara - Imiquimod 5%, Imiquimod Vehicle manufactured by Taro
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
20
States / cities
Gilbert, Arizona • Tempe, Arizona • Tuscon, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nanocytology Test to Evaluate Skin Cancer in High Risk Patients

NCT01905891
View directory record Official record
Conditions
Actinic Keratosis, Squamous Cell Carcinoma
Interventions
Superficial shave biopsy
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Phase 3 Interventional Results available

A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp

NCT01541553
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Cryotherapy, Vehicle, Ingenol metabute
Procedure · Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
35
States / cities
Fremont, California • Oceanside, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp

NCT02611804
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Diclofenac sodium, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
492 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
30
States / cities
Mesa, Arizona • Tucson, Arizona • Fremont, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Phase 1 Interventional Results available

Daylight Photodynamic Therapy for Actinic Keratosis

NCT03322293
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Aminolevulinic Acid Topical 20% Topical Solution, BLU-U blue light phototherapy illuminator
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Jul 21, 2026, 11:25 AM EDT
Recruiting Phase 2 Interventional

The Effect of Topical Imipramine on Photodynamic Therapy-Mediated Immunosuppression on Forearms or Face on US Veterans

NCT06778434
View directory record Official record
Conditions
Actinic Keratosis, Imipramine, Photodynamic Therapy
Interventions
Imipramine, Control Vehicle
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period

NCT03116698
View directory record Official record
Conditions
Actinic Keratosis (AK)
Interventions
Low dose DFD07 once daily, High dose DFD07 once daily, High dose DFD07 twice daily, Placebo twice daily
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
20
States / cities
Cerritos, California • Fremont, California • Palm Springs, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Jul 21, 2026, 11:25 AM EDT
Recruiting Early Phase 1 Interventional

A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients

NCT07286318
View directory record Official record
Conditions
Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Actinic Keratosis (AK), Organ Transplant Recipient
Interventions
Topical niacinamide 5% cream, Sunscreen
Drug
Lead sponsor
Marissa Lobl
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 21, 2026, 11:25 AM EDT